Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

New Indication Alert: MSD’s Keytruda® (Pembrolizumab) Approved in Canada for MSI-H or dMMR Solid Tumours

Sep 12, 2024

On 12 September 2024, Merck (known as MSD outside the US and Canada) announced that Health Canada has approved Keytruda® (pembrolizumab) as monotherapy for treatment of unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumours that have progressed following prior treatment and which have no satisfactory alternative treatment options.

Keytruda® was first approved in Canada in 2015 and has numerous cancer indications (alone or in combination) including melanoma, bladder cancer, gastric cancer, and adenocarcinoma.